Carboprost tromethamine is the tromethamine salt of 15-methyl-prostaglandin F2α. The product is a pharmaceutical-grade active pharmaceutical ingredient supplied for intramuscular injection at a concentration of 250 µg carboprost per mL and handled as an oral solid-dosage development candidate for tablet, capsule, and granule formats under restricted experimental protocols. The molecular formula of the salt is C25H47NO8, corresponding to a molar mass of 489.64 g/mol. The CAS registry number for the tromethamine salt is 58551-69-2. The 15-methyl substitution suppresses rapid inactivation by 15-hydroxyprostaglandin dehydrogenase, prolonging myometrial contractile response relative to endogenous prostaglandin F2α. Two release configurations constitute the principal model distinction for the product: an injectable-grade API released against bacterial endotoxin, sterility, and particulate matter specifications under USP <71>, USP <85>, and USP <788>, and a dry-processing development grade with particle-size and flow attributes controlled by laser diffraction under ISO 13320 and shear cell testing under ASTM D6128. The World Health Organization ATC code is G02AD04.

What Distinguishes 15-Methyl Prostaglandin F2α Tromethamine from Other Uterotonics?

Pharmacologically, carboprost tromethamine agonizes the prostaglandin F2α receptor, activating Gq-mediated phospholipase C and increasing intracellular calcium in uterine smooth muscle. This mechanism differs from oxytocin, a nonapeptide that binds the Gq-coupled oxytocin receptor and is metabolized by circulating oxytocinase; from methylergonovine, an ergot alkaloid acting on serotonin and α-adrenergic receptors; and from misoprostol, a prostaglandin E1 analogue with broader smooth-muscle activity. The 15-methyl group confers resistance to oxidation by 15-hydroxyprostaglandin dehydrogenase without altering receptor subclass selectivity, producing a longer duration of action than unmodified prostaglandin F2α. Clinical use is confined to deep intramuscular injection at a concentration of 250 µg carboprost per mL, with repeat doses of 250 µg administered at intervals of 15 to 90 minutes and a maximum cumulative dose of 2 mg. Intravenous administration is contraindicated because of the risk of severe bronchoconstriction and hemodynamic instability.

Release testing for the injectable-grade API requires identity confirmation by infrared absorption spectrophotometry under USP <197A>, with assay and specified organic impurities determined by high-performance liquid chromatography using system suitability criteria defined in USP <621>. Water content is determined by Karl Fischer titration according to USP <921> Method Ia. Residual solvents are controlled under USP <467> and ICH Q3C; elemental impurities are managed under ICH Q3D. Because the prostaglandin is oxidation-sensitive, forced degradation studies under ICH Q1A(R2) and ICH Q1B are used to qualify oxidant, heat, and photolytic stress. For sterile finished product, bacterial endotoxins are tested by Limulus amebocyte lysate under USP <85>, sterility by membrane filtration under USP <71>, and particulate matter in the final injection by light obscuration under USP <788>. Subvisible particle counts in the injectable presentation must satisfy the limits for small-volume parenterals.

Residual solvent control follows ICH Q3C. When methanol is used in the final crystallization, the limit is 3000 ppm; acetone and isopropanol limits are 5000 ppm each. Class 1 solvents such as benzene and carbon tetrachloride are excluded from the manufacturing stream. The certificate of analysis must report all Class 2 and Class 3 solvent levels against the patient daily-dose equations in ICH Q3C. At relative humidity above 60% RH, the tromethamine salt can absorb enough moisture to reduce powder flow and accelerate hydrolytic degradation. Controlled humidity below 60% RH and nitrogen-blanketed packaging are therefore used during API dispensing and storage.

Formulation-Grade Attributes for Low-Dose Tablet, Capsule, and Granule Manufacture

Manufacture of low-dose oral solid dosage forms from carboprost tromethamine requires content uniformity strategies appropriate for a finished unit containing less than 1 mg of active substance. Direct compression and capsule filling require geometric preblending with pre-screened excipients, typically lactose monohydrate or microcrystalline cellulose, and evaluation of blend uniformity according to USP <905>. Wet granulation is limited by the compound’s susceptibility to acid-catalyzed degradation and oxidation; therefore, dry granulation or direct compression is preferred. Particle size distribution, bulk density, and flow function coefficient are determined by sieve analysis, tapped density testing under USP <616>, and shear cell methods such as ASTM D6128. Formulation development must include excipient compatibility screening under ICH Q8; published data for oral carboprost tromethamine tablet and capsule pharmacokinetics is limited, and bioequivalence to the intramuscular route has not been established in compendial monographs.

Analytical method validation for low-dose carboprost tromethamine follows ICH Q2(R1). Quantification at the 250 µg per unit level may require liquid chromatography-tandem mass spectrometry because ultraviolet absorbance of the prostaglandin is weak. If high-performance liquid chromatography with derivatization is used, system precision and limit of quantitation must be established at or below 50% of the nominal dose. For capsule formats, gelatin shells containing 13 to 16% moisture can transfer water to the API; hydroxypropyl methylcellulose capsules with lower equilibrium moisture are therefore evaluated when long-term chemical stability is a constraint. Tablet compression with magnesium stearate at 0.25 to 0.50% w/w requires monitoring of lubricant-sensitivity and tablet tensile strength. Equipment cleaning and line changeover must be validated to prevent cross-contamination of prostaglandin-sensitive components; analytical wipe limits are set using health-based exposure limits under ISPE Risk-MaPP.

When Injectable Presentation Is Required, Aseptic Processing and Endotoxin Control Depend on More than API Purity

Manufacture of the intramuscular injection at 250 µg carboprost per mL is not equivalent to simple dissolution of the API. The bulk solution in the reference product contains benzyl alcohol as preservative at a concentration of 9 mg/mL, with sodium chloride for tonicity adjustment in water for injection. The API is dissolved under nitrogen because of oxidative lability, and the solution is sterilized by membrane filtration rather than terminal autoclaving. Container-closure integrity is evaluated according to USP <1207> after filling. The finished product requires visible particulate inspection and meets subvisible particulate limits under USP <788>. Process capability for filling low-dose preserved solutions must be validated across filling speeds and stoppering conditions; in-process checks include dose uniformity, pH, and preservative assay. Environmental monitoring for aseptic filling must meet the airborne particle classification for Grade A zones under ISO 14644-1. The final injection is stored under refrigeration at 2–8°C.

The tromethamine salt form is selected because the free acid form has limited aqueous solubility at physiological pH. Salt formation with tromethamine produces a water-soluble powder suitable for formulation of the 250 µg per mL injection without requiring organic cosolvents. This is a meaningful difference from dinoprostone or misoprostol, which are often formulated in non-aqueous vehicles or as dispersions. Within the prostaglandin F2α family, carboprost tromethamine differs from dinoprost tromethamine by the 15-methyl substituent. Dinoprost is rapidly metabolized by 15-hydroxyprostaglandin dehydrogenase, requiring more frequent administration or continuous infusion. Carboprost tromethamine is therefore selected when a longer-acting intramuscular agent is required after oxytocin failure.

In contrast to oxytocin, which is thermolabile and requires strict cold-chain transport from the point of manufacture, carboprost tromethamine is handled as a stability-sensitive prostaglandin but is supplied as a salt to improve water solubility. Methylergonovine is contraindicated in patients with hypertension or preeclampsia, whereas carboprost tromethamine is restricted in patients with active cardiovascular or pulmonary disease, including asthma. Misoprostol is administered by oral, sublingual, and rectal routes because it is a prostaglandin E1 analogue with a different receptor profile, but it produces pyrexia and diarrhea more frequently. These differences define product-specific safety and handling boundaries rather than interchangeability.